Adagio Medical Holdings (ADGM) EBITDA (2023 - 2026)

Adagio Medical Holdings has disclosed EBITDA across 4 years of filings, most recently posting -$4.9 million for Q2 2026.

• In Q2 2026, EBITDA fell 4.6% year-over-year to -$4.9 million; the TTM figure through Jun 2026 stood at -$19.8 million (up 14.55% YoY), while the FY2025 annual figure was -$21.9 million, up 64.96% from the prior year.
• EBITDA came in at -$4.9 million for Q2 2026 at Adagio Medical Holdings, up from -$5.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$4.0 million in Q4 2025 to a low of -$9.1 million in Q3 2023.
• Average EBITDA over 4 years is -$6.0 million, with a median of -$5.3 million recorded in 2023.
• Year-over-year, EBITDA soared 51.27% in 2024 and fell 29.29% in 2025.
• Over 4 years, EBITDA stood at -$5.3 million in 2023, then climbed by 17.03% to -$4.4 million in 2024, then increased by 10.33% to -$4.0 million in 2025, then slipped by 24.34% to -$4.9 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$4.9 million in Q2 2026, -$5.2 million in Q1 2026, and -$4.0 million in Q4 2025.